Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical ...

The Samsung Galaxy S26, OnePlus 15, and Google Pixel 10 all land within shouting distance of each other on price, run the same operating system, and target roughly the same buyer. But spend any real ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Both VOO and IVV track the S&P 500 with identical returns and expense ratios. IVV offers a slightly higher dividend yield and marginally heavier tech weighting. Liquidity, risk, and overall portfolio ...

Barreling toward the end of its cash runway, GRI Bio has shared phase 2a data in idiopathic pulmonary fibrosis (IPF) and made the case for further development of its potentially disease-modifying ...

Crafting clear mission and vision statements is critical to shaping company identity, motivating employees and guiding decision-making. A mission statement defines the current scope and purpose of the ...

All eyes will be on hip hop trailblazers this weekend. Iconic labels, Cash Money Records and No Limit Records, will go head-to-head at ComplexCon in Las Vegas. It marks the return of Verzuz, the ...

Hampshire made it clear throughout the season which opponent it wanted to dethrone. “ Huntley’s always kind of been that rival, and we’ve had a fire under our butts the whole season,” Whip-Purs senior ...

Toyota or Honda? RAV4 or CR-V? These are the types of decisions that keep mainstream SUV shoppers up at night. Now, with an all-new RAV4 throwing its tires in the ring, things have only gotten more ...

"Year to date" sales for 2022, 2023, 2024, and 2025 sales are shown in series at the top of the table and then just below a comparison of 2025 versus 2024 and 2025 versus 2023 is displayed. This ...

More than 10 years after bringing one of the first idiopathic pulmonary fibrosis (IPF) drugs to market, Boehringer Ingelheim is freshening up its leadership in the rare lung disease space with a newly ...